Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Abbott Laboratories (ABT)

Abbott Laboratories (ABT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

What to Expect From Vertex Pharmaceuticals’ Q1 2026 Earnings Report

With a market cap of $112.9 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a biotechnology company focused on developing and commercializing innovative therapies, best known for its leading portfolio of cystic fibrosis treatments, including TRIKAFTA/KAFTRIO, ALYFTREK, and KALYDECO. It also advances medicines for serious diseases such as sickle cell disease, beta thalassemia, diabetes, kidney disease, and acute pain through a strong research pipeline and strategic collaborations.

The company is slated to announce its fiscal Q1 2026 results on Monday, May 4, after the market closes. Ahead of the event, analysts expect VRTX to report an adjusted EPS of $3.88, up 9.3%...

Fundamentals

See More
  • Market Capitalization, $K 174,688,192
  • Shares Outstanding, K 1,741,657
  • Annual Sales, $ 44,328 M
  • Annual Income, $ 6,524 M
  • EBIT $ 9,735 M
  • EBITDA $ 12,851 M
  • 60-Month Beta 0.79
  • Price/Sales 4.04
  • Price/Cash Flow 14.69
  • Price/Book 3.38

Options Overview Details

View History
  • Implied Volatility 31.05% (+0.49%)
  • Historical Volatility 19.46%
  • IV Percentile 95%
  • IV Rank 71.97%
  • IV High 36.54% on 04/11/25
  • IV Low 16.97% on 08/12/25
  • Expected Move (DTE 5) 4.17 (4.15%)
  • Put/Call Vol Ratio 3.09
  • Today's Volume 17,538
  • Volume Avg (30-Day) 11,749
  • Put/Call OI Ratio 1.02
  • Today's Open Interest 159,886
  • Open Int (30-Day) 154,364
  • Expected Range 96.14 to 104.47

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $1.14
  • Number of Estimates 9
  • High Estimate $1.17
  • Low Estimate $1.13
  • Prior Year $1.09
  • Growth Rate Est. (year over year) +4.59%

Price Performance

See More
Period Period Low Period High Performance
1-Month
99.34 +0.97%
on 04/10/26
111.86 -10.33%
on 03/17/26
-10.25 (-9.27%)
since 03/10/26
3-Month
99.34 +0.97%
on 04/10/26
126.61 -20.78%
on 01/12/26
-25.62 (-20.35%)
since 01/09/26
52-Week
99.34 +0.97%
on 04/10/26
139.06 -27.87%
on 06/24/25
-24.20 (-19.44%)
since 04/10/25

Most Recent Stories

More News
What to Expect From Vertex Pharmaceuticals’ Q1 2026 Earnings Report

Vertex Pharmaceuticals is set to report its first-quarter results next month, and analysts are expecting high single-digit growth in earnings.

ABT : 100.30 (-2.36%)
XLV : 147.31 (-1.35%)
$SPX : 6,816.89 (-0.11%)
VRTX : 436.27 (-2.35%)
Zimmer Biomet’s Quarterly Earnings Preview: What You Need to Know

Zimmer Biomet is poised to report its first-quarter results in the near future, and Wall Street anticipates a measured, single-digit increase in earnings.

ZBH : 93.12 (+0.10%)
ABT : 100.30 (-2.36%)
XLV : 147.31 (-1.35%)
$SPX : 6,816.89 (-0.11%)
New survey finds most Americans believe chronic diseases are preventable, but only 1 in 4 feel confident in how to care for their health

With chronic disease on the rise, a new survey from Abbott shows information overload, confusion and cost leave many Americans struggling, worrying about how to stay healthy

ABT : 100.30 (-2.36%)
What You Need To Know Ahead of Humana's Earnings Release

Humana is scheduled to release its first-quarter results later this month, with analysts projecting double-digit earnings drop.

HUM : 192.15 (-2.62%)
ABT : 100.30 (-2.36%)
XLV : 147.31 (-1.35%)
$SPX : 6,816.89 (-0.11%)
A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?

Abbott Laboratories' recent stock price dip contrasts with its strong Medical Devices division, creating a noteworthy opportunity for dividend investors.

ABT : 100.30 (-2.36%)
Comparing 2 Healthcare Giants: Which Dividend Aristocrat Will Keep Paying Out for Generations to Come?

Johnson & Johnson offers scale and stability, but Abbott’s cheaper valuation, higher yield, and stronger upside make it the more attractive pick now.

ABT : 100.30 (-2.36%)
JNJ : 238.46 (-1.18%)
1 Healthcare Stock on Our Watchlist and 2 We Find Risky

1 Healthcare Stock on Our Watchlist and 2 We Find Risky

ABT : 100.30 (-2.36%)
AORT : 37.63 (+3.07%)
QDEL : 13.85 (-2.12%)
Buy the Dip: These 3 Over-$100 Stocks Just Hit New 52-Week Lows

Among the 128 new 52-week lows on the NYSE on Tuesday, there were five with share prices of $100 or higher. Not all of them are worth buying on the dip. We rate three that could be.

ABT : 100.30 (-2.36%)
PGR : 194.13 (-2.88%)
AVB : 169.78 (+0.75%)
This Dividend King Is Down 26%. When Will It Bounce Back?

Abbott Laboratories is down 26% from its 52-week high due to a soft quarter. With 54 consecutive years of dividend hikes and guidance calling for mid-single-digit organic sales growth plus 10% EPS expansion,...

ABT : 100.30 (-2.36%)
JNJ : 238.46 (-1.18%)
MDT : 87.21 (-0.80%)
$INX : 6,816.89 (-0.11%)
Abbott expands access to Precision Oncology portfolio through integration with Flatiron's OncoEMR® platform

ABBOTT PARK, Ill. and NEW YORK , March 30, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare company, and Flatiron Health, a leading healthtech company advancing point-of-care solutions...

ABT : 100.30 (-2.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures...

See More

Key Turning Points

3rd Resistance Point 105.70
2nd Resistance Point 104.23
1st Resistance Point 102.27
Last Price 100.30
1st Support Level 98.84
2nd Support Level 97.37
3rd Support Level 95.41

See More

52-Week High 139.06
Fibonacci 61.8% 123.89
Fibonacci 50% 119.20
Fibonacci 38.2% 114.51
Last Price 100.30
52-Week Low 99.34

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.